PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported April 22, 2020

Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 13107-031-34

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Recall #
D-1235-2020
Affected scope
56208 units
Initiated
March 18, 2020
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Aurobindo Pharma USA Inc. recalled Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharm… - a moderate-severity action.

Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharm… was recalled by Aurobindo Pharma USA Inc. in April 22, 2020. Reason: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed. Check the official notice for the remedy. Verify recall #D-1235-2020 with the FDA Drug before acting.

The recall

Aurobindo Pharma USA Inc. issued this moderate-severity FDA Drug recall-CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed.

Moderate
severity level
56K units
affected scope
Class II
classification
April 22, 2020
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1235-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-1235-2020) was formally reported on April 22, 2020, with the manufacturer initiating the action on March 18, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Aurobindo Pharma USA Inc. is listed as the recalling firm, operating out of East Windsor, NJ. Federal records list the affected scope as 56208 units.

The documented reason for this recall is: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed Distribution data in the federal record shows the product reached: Nationwide within the United States. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

56208 units

Related Recalls

6

5 from same agency

Product description

Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 13107-031-34

Reason for recall

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-1235-2020
Date reported April 22, 2020
Date initiated March 18, 2020
Recalling firm Aurobindo Pharma USA Inc.
Firm location East Windsor, NJ
Affected scope 56208 units
Distribution Nationwide within the United States

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

Scale of Impact

56208 units units affected - limited or regional distribution scale.

Regional (<10K units) -
Multi-state (10K – 100K units) ✓ This recall
Large-scale (100K – 1M units) -
Massive (≥1M units) -

Bracket cutoffs follow federal recall-disclosure conventions; bar widths scale linearly within each bracket. Source: PlainRecalls analysis of U.S. Food and Drug Administration filings.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-1235-2020) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 13107-031-34. Recalled by Aurobindo Pharma USA Inc.. Units affected: 56208 units.
Why was this product recalled?
CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed
Which agency issued this recall?
This recall was issued by the FDA Drug on April 22, 2020. Severity: Moderate. Recall number: D-1235-2020.
Where was the recalled product distributed?
Distribution: Nationwide within the United States.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-1235-2020) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 22, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.